GlassScriptPhysician profile
William M Cicio
NPI 1548201569
$4,043.44
in general payments reported to CMS, 2019-2025
34 companies · $38.36 in 2025
The $38.36 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $213 · 2021: $402 · 2022: $1,479 · 2023: $981 · 2024: $693 · 2025: $38.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $380.68 | 2019-2024 | |
| Abbvie INC. | $360.08 | 2022-2023 | Vraylar |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $322.57 | 2019-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $247.65 | 2019-2023 | Farxiga |
| Medtronic, INC. | $235.58 | 2021-2022 | |
| Vital Connect, INC | $232.89 | 2022-2024 | Vitalpatch Rtm |
| Idorsia Pharmaceuticals US INC | $224.96 | 2023-2024 | Quviviq |
| Biotronik INC. | $185.58 | 2021-2025 | Selectra |
| Inari Medical, INC. | $136.68 | 2022 | |
| Abbott Laboratories | $124.49 | 2021-2024 | Jot Dx |
| Teva Pharmaceuticals USA, INC. | $124.32 | 2023 | Austedo Xr |
| Axsome Therapeutics, INC. | $123.24 | 2023 | Sunosi |
| Neurocrine Biosciences, INC. | $123.17 | 2024 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $121.35 | 2024 | Voquezna |
| Lantheus Medical Imaging, INC. | $117.59 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $117.31 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $114.80 | 2022 | |
| Tris Pharma INC | $110.73 | 2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| E.R. Squibb & Sons, L.L.C. | $107.52 | 2020-2023 | Camzyos |
| Alkermes, INC. | $90.88 | 2022 | |
| Janssen Pharmaceuticals, INC | $89.81 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $74.57 | 2022-2023 | Verquvo |
| Amgen INC. | $45.13 | 2020 | |
| Cvrx, INC. | $32.99 | 2022-2024 | Barostim Neo System |
| Lundbeck LLC | $30.31 | 2020 | |
| Portola Pharmaceuticals, LLC | $23.42 | 2019 | |
| Daiichi Sankyo INC. | $23.32 | 2022 | |
| Edwards Lifesciences Corporation | $20.98 | 2022 | |
| Amarin Pharma, INC. | $19.18 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.64 | 2020 | |
| Astellas Pharma US INC | $17.75 | 2019 | |
| Boston Scientific Corporation | $17.13 | 2019 | |
| Preventice Services, LLC | $15.61 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cicio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.